MarginsXMarginsX
Home › Markets › Health Care › NEOG

Neogen Corporation (NEOG)

NEOG trades on Nasdaq in Health Care, Biotechnology: In Vitro & In Vivo Diagnostic Substances. Numbers below come from the Nasdaq screener and SEC filings, each with its source.

Price · November 16, 2026
$10.88
-3.12% on the day
Market cap
$2.4B
Mid cap
Revenue · 2026
$870.4M
-2.7% on 2025
Net income · 2026
-$7.9M
-0.9% net margin

Price, change, market cap, sector and industry: Nasdaq stock screener, as of November 16, 2026. Revenue: SEC 10-K (us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax), fiscal year ended 2026-05-31, https://www.sec.gov/Archives/edgar/data/711377/000119312526326092/0001193125-26-326092-index.htm. Net income: SEC 10-K (us-gaap:NetIncomeLoss), fiscal year ended 2026-05-31.

Profile

FieldValue
TickerNEOG on Nasdaq
SectorHealth Care
IndustryBiotechnology: In Vitro & In Vivo Diagnostic Substances
CountryUnited States
IPO year1989
SEC CIK0000711377
SEC industry codeIn Vitro & In Vivo Diagnostic Substances
Incorporated inMI

Financials · 2026

LineValue
Revenue$870.4M
Net income-$7.9M
Operating income-$21.6M
Net margin-0.9%
Operating margin-2.5%
Revenue growth-2.7%
Cash$185.5M
Total assets$3.3B
P/E (computed)Net income was not positive
P/S (computed)2.7×

Warning signs

Cash runway
Cash-flow positive
$172.0M cash at August 31, 2026
Share count, 1 year
+0.5%
2025-08-31 to 2026-08-31 · +0.9% over 3 years
Going-concern doubt
No
10-Q filed October 7, 2026
Insider net buying, 12 months
$7K
Through September 30, 2026
SignFindingSource
Going concernNo going-concern finding.10-Q 2026-10-07
Cash and burn$172.0M cash; operating cash flow $21.3M a quarter.Report 2026-08-31
Shares outstanding218,306,034 (2026-08-31); 217,298,626 a year earlier; 216,310,582 three years earlier.Cover page 2026-08-31
Reverse splits, 3 yearsNone foundNone on EDGAR
Shelf and offerings, 12 months0 S-3/F-3 shelf filings; 0 424B5 takedownsNone on EDGAR
Exchange deficiency notices, 12 monthsNoneNone on EDGAR
AuditorBDO USA, P.C., Grand Rapids, Michigan, United StatesPCAOB Form AP 2026-08-05
Late filings, 12 monthsNoneNone on EDGAR
Insider trades, 12 monthsBought $7K, sold $0 on the open marketSEC Forms 3/4/5 data sets 2026-09-30

From SEC EDGAR submissions, EDGAR full-text search, SEC's Forms 3/4/5 data sets and PCAOB Form AP; computed November 16, 2026. Runway is cash divided by average quarterly operating cash burn. Dilution compares cover-page share counts, corrected for recorded splits.

Quarterly results

QuarterRevenueNet incomeOp. cash flowCashTotal debtTTM revenueSource
Q1 2027
2026-08-31
$222.8M-$11.9M$12.9M$172.0M$1.6B$884.0M10-Q 2026-10-07
Q4 2026
2026-05-31
$225.3M-$11.3M$30.2M$185.5M$793.7M$870.4M10-K 2026-07-30
Q3 2026
2026-02-28
$211.2M-$17.0M$22.7M$159.9M$1.6B$870.6M10-Q 2026-04-09
Q2 2026
2025-11-30
$224.7M-$15.9M$19.5M$145.3M$1.6B$880.4M10-Q 2026-01-08
Q1 2026
2025-08-31
$209.2M$36.3M$10.8M$138.9M$1.6B$887.0M10-Q 2026-10-07
Q4 2025
2025-05-31
$225.5M-$612.2M$16.4M$129.0M$894.1M$894.7M10-K 2026-07-30
Q3 2025
2025-02-28
$221.0M-$10.9M$19.5M$127.7M$890.6M$906.0M10-Q 2026-04-09
Q2 2025
2024-11-30
$231.3M-$456.3M$40.3M$140.2M$889.9M$913.8M10-Q 2026-01-08

From SEC XBRL company facts. Quarters a filing gives only as year-to-date are computed as differences (Q4 is the fiscal year minus nine months).

Key SEC documents

DocumentFormFiled
Latest prospectus or offering document424B32022-08-04
Latest annual report10-K2026-07-30
Latest quarterly / interim10-Q2026-10-07
Latest current report8-K2026-11-04
Latest proxyDEFA14A2026-09-28

Source: SEC EDGAR submissions feed, 1,000 recent filings. All filings on EDGAR.

Price moves

WindowReturn
1 week-4.5%
1 month-4.3%
3 months-5.6%
Year to date+60.7%
1 year+76.3%
From 52-week high-19.7%

Source: Yahoo Finance daily closes, last bar 2026-11-13. Computed by MarginsX from daily closes; cap, sector and tier from the Nasdaq screener.

Peers in Biotechnology: In Vitro & In Vivo Diagnostic Substances

TickerCompanyPriceDayMarket cap
CLDXCelldex Therapeutics Inc.$28.59-0.83%$2.2B
NTLAIntellia Therapeutics Inc.$9.86+1.65%$1.4B
LNTHLantheus Holdings Inc.$101.72+0.13%$6.7B
ORKAOruka Therapeutics Inc.$99.24-5.80%$6.7B
QDELQuidelOrtho Corporation$10.21-4.93%$700.5M
QUITAchieve Life Sciences Inc. Common Shares$6.06-4.11%$666.8M
NNNNAnbio Biotechnology$3.88+1.57%$558.3M
MYGNMyriad Genetics Inc.$5.57-1.59%$534.3M

The full dossier has every filing, three years of financials, private raises and the people who signed them.

Open the full dossier